CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Clinical trial NCT06209619 · RECRUITING

Trial details

NCT number: NCT06209619
Sponsor: Nathan Denlinger
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-Cell Non-Hodgkin Lymphoma-Recurrent Diffuse Large B-Cell Lymphoma-Recurrent Follicular Lymphoma-Recurrent High Grade B-Cell Lymphoma-Recurrent Primary Mediastinal Large B-Cell Lymphoma-Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent B-Cell Non-Hodgkin Lymphoma-Refractory Diffuse Large B-Cell Lymphoma-Refractory Follicular Lymphoma-Refractory High Grade B-Cell Lymphoma-Refractory Primary Mediastinal Large B-Cell Lymphoma-Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory

Start date: 2024-01-29
Primary completion: 2026-12-31
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.